NDAQ Nasdaq Inc.

Annual Changes to the Nasdaq Biotechnology Index

Annual Changes to the Nasdaq Biotechnology Index

NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the results of the annual reconstitution of the Nasdaq Biotechnology Index (Nasdaq: NBI), which will become effective prior to market open on Monday, December 21, 2020.

The Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (Nasdaq®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB).

The following 100 securities will be added to the Index:

EXCHANGESYMBOLCOMPANY NAME
NasdaqABUSArbutus Biopharma Corporation
NasdaqADAPAdaptimmune Therapeutics plc
NasdaqAKUSAkouos, Inc.
NasdaqALTAltimmune, Inc.
NasdaqALVRAlloVir, Inc.
NasdaqALXOALX Oncology Holdings Inc.
NasdaqAMTIApplied Molecular Transport Inc.
NasdaqANNXAnnexon, Inc.
NasdaqAPLTApplied Therapeutics, Inc.
NasdaqAPREAprea Therapeutics, Inc.
NasdaqARCTArcturus Therapeutics Holdings Inc.
NasdaqARQTArcutis Biotherapeutics, Inc.
NasdaqAVDLAvadel Pharmaceuticals plc
NasdaqAZNAstraZeneca PLC
NasdaqBDTXBlack Diamond Therapeutics, Inc.
NasdaqBEAMBeam Therapeutics Inc.
NasdaqBNTXBioNTech SE
NasdaqCABACabaletta Bio, Inc.
NasdaqCALACalithera Biosciences, Inc.
NasdaqCDXSCodexis, Inc.
NasdaqCLVSClovis Oncology, Inc.
NasdaqCNCEConcert Pharmaceuticals, Inc.
NasdaqCNSTConstellation Pharmaceuticals, Inc.
NasdaqCRNXCrinetics Pharmaceuticals, Inc.
NasdaqCRTXCortexyme, Inc.
NasdaqFMTXForma Therapeutics Holdings, Inc.
NasdaqFPRXFive Prime Therapeutics, Inc.
NasdaqFREQFrequency Therapeutics, Inc.
NasdaqFULCFulcrum Therapeutics, Inc.
NasdaqFUSNFusion Pharmaceuticals Inc.
NasdaqGBIOGeneration Bio Co.
NasdaqGMDAGamida Cell Ltd.
NasdaqHARPHarpoon Therapeutics, Inc.
NasdaqIDYAIDEAYA Biosciences, Inc.
NasdaqIGMSIGM Biosciences, Inc.
NasdaqIMABI-MAB
NasdaqIMUXImmunic, Inc.
NasdaqIMVTImmunovant, Inc.
NasdaqINZYInozyme Pharma, Inc.
NasdaqISEEIVERIC bio, Inc.
NasdaqITOSiTeos Therapeutics, Inc.
NasdaqJNCEJounce Therapeutics, Inc.
NasdaqKALAKala Pharmaceuticals, Inc.
NasdaqKALVKalVista Pharmaceuticals, Inc.
NasdaqKDMNKadmon Holdings, Inc.
NasdaqKDNYChinook Therapeutics, Inc.
NasdaqKLDOKaleido Biosciences, Inc.
NasdaqKMDAKamada Ltd.
NasdaqKNSAKiniksa Pharmaceuticals, Ltd.
NasdaqKROSKeros Therapeutics, Inc.
NasdaqKRYSKrystal Biotech, Inc.
NasdaqKZRKezar Life Sciences, Inc.
NasdaqLEGNLegend Biotech Corporation
NasdaqLRMRLarimar Therapeutics, Inc.
NasdaqMDGLMadrigal Pharmaceuticals, Inc.
NasdaqMNOVMediciNova, Inc.
NasdaqMRNSMarinus Pharmaceuticals, Inc.
NasdaqMRSNMersana Therapeutics, Inc.
NasdaqNKNantKwest, Inc.
NasdaqNKTXNkarta, Inc.
NasdaqNLTXNeoleukin Therapeutics, Inc.
NasdaqNRIXNurix Therapeutics, Inc.
NasdaqNVAXNovavax, Inc.
NasdaqNXTCNextCure, Inc.
NasdaqOCULOcular Therapeutix, Inc.
NasdaqODTOdonate Therapeutics, Inc.
NasdaqORICOric Pharmaceuticals, Inc.
NasdaqOVIDOvid Therapeutics Inc.
NasdaqPAHCPhibro Animal Health Corporation
NasdaqPANDPandion Therapeutics Inc.
NasdaqPASGPassage Bio, Inc.
NasdaqPCVXVaxcyte, Inc.
NasdaqPLRXPliant Therapeutics, Inc.
NasdaqPRTKParatek Pharmaceuticals, Inc.
NasdaqPRVBProvention Bio, Inc.
NasdaqPSTXPoseida Therapeutics, Inc.
NasdaqRAPTRAPT Therapeutics, Inc.
NasdaqRDHLRedhill Biopharma Ltd.
NasdaqREPLReplimune Group, Inc.
NasdaqRLAYRelay Therapeutics, Inc.
NasdaqRLMDRelmada Therapeutics, Inc.
NasdaqRNAAvidity Biosciences, Inc.
NasdaqRPRXRoyalty Pharma plc
NasdaqRPTXRepare Therapeutics Inc.
NasdaqRVMDRevolution Medicines, Inc.
NasdaqSELBSelecta Biosciences, Inc.
NasdaqSMMTSummit Therapeutics Inc.
NasdaqSNDXSyndax Pharmaceuticals, Inc.
NasdaqSPROSpero Therapeutics, Inc.
NasdaqSTROSutro Biopharma, Inc.
NasdaqSURFSurface Oncology, Inc.
NasdaqSWTXSpringWorks Therapeutics, Inc.
NasdaqTCRRTCR2 Therapeutics Inc.
NasdaqVIEViela Bio, Inc.
NasdaqVIRVir Biotechnology, Inc.
NasdaqVSTMVerastem, Inc.
NasdaqVYNEVYNE Therapeutics Inc.
NasdaqXENEXenon Pharmaceuticals Inc.
NasdaqZIOPZIOPHARM Oncology Inc
NasdaqZNTLZentalis Pharmaceuticals, Inc.

As a result of the reconstitution, the following 16 securities will be removed from the Index:

EXCHANGESYMBOLCOMPANY NAME
NasdaqADMAADMA Biologics Inc
NasdaqAMRSAmyris, Inc.
NasdaqAXNXAxonics Modulation Technologies, Inc.
NasdaqCERSCerus Corporation
NasdaqCRBPCorbus Pharmaceuticals Holdings, Inc.
NasdaqEOLSEvolus, Inc.
NasdaqEYPTEyePoint Pharmaceuticals, Inc.
NasdaqGLYCGlycoMimetics, Inc.
NasdaqGRTSGritstone Oncology, Inc.
NasdaqLXRXLexicon Pharmaceuticals, Inc.
NasdaqNVCRNovoCure Limited
NasdaqOPTNOptiNose, Inc.
NasdaqPRQRProQR Therapeutics N.V.
NasdaqQTRXQuanterix Corporation
NasdaqSLDBSolid Biosciences Inc.
NasdaqTECHBio-Techne Corp

About Nasdaq Global Indexes

Nasdaq Global Indexes has been creating innovative, market-leading, transparent indexes since 1971. Today, our index offering spans geographies and asset classes and includes diverse families such as the Dividend and Income (includes Dividend Achievers), Dorsey Wright, Fixed Income (includes BulletShares®), Global Equity, Green Economy, Nordic and Commodity indexes. We continuously offer new opportunities for financial product sponsors across a wide-spectrum of investable products and for asset managers to measure risk and performance. Nasdaq also provides exchange listing, custom index and design solutions to financial organizations worldwide.

About Nasdaq

Nasdaq (Nasdaq: NDAQ) is a global technology company serving the capital markets and other industries. Our diverse offering of data, analytics, software and services enables clients to optimize and execute their business vision with confidence. To learn more about the company, technology solutions and career opportunities, visit us on , on Twitter , or at .

Media Relations Contact

Emily Pan

(646) 637-3964

Issuer & Investor Contact

Index Client Services

The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular financial product or an overall investment strategy. Neither Nasdaq, Inc. nor any of its affiliates makes any recommendation to buy or sell any financial product or any representation about the financial condition of any company or fund. Statements regarding Nasdaq’s proprietary indexes are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.

- NDAQG-



EN
12/12/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nasdaq Inc.

 PRESS RELEASE

Nasdaq to Hold First Quarter 2026 Investor Conference Call

Nasdaq to Hold First Quarter 2026 Investor Conference Call NEW YORK, April 01, 2026 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) has scheduled its first quarter 2026 financial results announcement. Who:Nasdaq’s CEO, CFO, and additional members of its senior management team  What:Review Nasdaq’s first quarter 2026 financial results  When:Thursday, April 23, 2026Results Call: 8:00 AM Eastern   Senior management will be available for questions from the investment community following prepared remarks. All participants can access the conference via webcast through the Nasdaq Investor Relations w...

 PRESS RELEASE

Nasdaq Concludes Public Consultation on Nasdaq-100 Index® Methodology

Nasdaq Concludes Public Consultation on Nasdaq-100 Index® Methodology NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the resolution of its public consultation on proposed enhancements to the Nasdaq-100 Index® methodology. Following a transparent and open comment period, that opened February 2 and closed February 27, 2026, Nasdaq Global Indexes, has approved updates to the Nasdaq-100 Index methodology, effective May 1, 2026. Nasdaq Global Indexes periodically reviews index methodologies through standard governance processes, and feedback submitted durin...

 PRESS RELEASE

Nasdaq Announces Mid-Month Open Short Interest Positions in Nasdaq Sto...

Nasdaq Announces Mid-Month Open Short Interest Positions in Nasdaq Stocks as of Settlement Date March 13, 2026 NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- At the end of the settlement date of March 13, 2026, short interest in 3,657 Nasdaq Global MarketSM securities totaled 16,179,628,406 shares compared with 15,794,218,322 shares in 3,629 Global Market issues reported for the prior settlement date of February 27, 2026. The mid-March short interest represents 2.42 days compared with 2.64 days for the prior reporting period. Short interest in 1,649 securities on The Nasdaq Capital MarketS...

 PRESS RELEASE

Nasdaq Halts American Rebel Holdings, Inc.

Nasdaq Halts American Rebel Holdings, Inc. NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading is halted in American Rebel Holdings, Inc. (Nasdaq: AREB) for additional information requested from the company. Previously, Nasdaq halted AREB at 19:50:00 on March 20, 2026 in connection with a previously announced reverse stock split. The last sale price of the company’s shares was $0.0646.  Trading will remain halted until American Rebel Holdings, Inc. has fully satisfied Nasdaq’s request for additional information. For news and additi...

 PRESS RELEASE

Nasdaq and Talos Partner to Advance Tokenized Collateral Management Ac...

Nasdaq and Talos Partner to Advance Tokenized Collateral Management Across Mainstream and Digital Asset Markets Integration of Talos' digital asset infrastructure with Nasdaq’s Calypso and Trade Surveillance platforms delivers unified market access, cross-asset risk management, and institutional-grade compliance NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) and Talos today announced a partnership to connect Talos' digital asset infrastructure with Nasdaq's Calypso and Trade Surveillance platforms to develop an integrated solution for managing tokenized collateral. T...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch